The workplace is a key environment to impact employees, families, and communities to prevent further opioid and substance misuse, addiction, and overdose. However, it is often overlooked as an ideal location to launch a prevention intervention or support strategy. Employees in recovery, seeking treatment, and dealing with mental distress require employer support. Supports should consider the diversity of the work force and be culturally appropriate. Several data sources, tools, and other resources exist to aid employers in supporting their employees and addressing the opioid epidemic; a few from the National Safety Council are discussed. As well as suitable strategies to strengthen workplace prevention interventions and treatment access, in light of the opioid epidemic, coronavirus pandemic, and workplace disparities.
MattsonCLTanzLJQuinnK, et al.
Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013-2019. MMWR Morb Mortal Wkly Rep2021;
70: 202–207.
2.
GladdenRMO’DonnellJMattsonCL, et al.
Changes in the opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine – 25 states, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep2019;
68: 737–744.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20-07-01-001, NSDUH Series H-55. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, September 2020.
5.
United Nations Office on Drugs and Crime. World drug report2015. Report for the United Nations. Report no. E.15.XI.6. Vienna: AT, May 2015.
6.
DasguptaNBeletskyLCiccaroneD.Opioid crisis: no easy fix to its social and economic determinant. Am J Public Health2018;
108: 182–186.
7.
HawkinsDPunnettLDavisL, et al. The contribution of occupation-specific factors to the deaths of despair, Massachusetts, 2005-2015. Ann Work Expo Health. Epub ahead of print 23 April 2021. DOI: 10.1093/annweh/wxab017.
HagemeierNE.Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care2018;
24: S200–S206.
10.
FlorenceCLuoFRiceK.The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend2021;
218: 108350.
FroneM.Alcohol and illicit drug use in the workforce and workplace. 1st ed.
Washington, DC:
American Psychological Association, 2012, p.31.
14.
HawkinsDRoelofsCLaingJ, et al.
Opioid-related overdose deaths by industry and occupation-Massachusetts, 2011-2015. Am J Ind Med2019;
62: 815–825.
15.
Kowalski-McGrawMGreen-McKenzieJPandalaiS, et al.
Characterizing the interrelationships of prescription opioids and benzodiazepine drugs with worker health and workplace hazards. J Occup Environ Med2017;
59: 1114–1126.
16.
ShawWSRoelofsCPunnettL.Work environment factors and prevention of opioid-related deaths. Am J Public Health2020;
110: 1235–1241.
17.
DongXSBrooksRBrownS.Musculoskeletal disorders and prescription opioid use among U.S. construction workers. J Occup Environ Med2020;
62: 973–979.
Occupational Safety and Health Administration. Ergonomics, www.osha.gov/ergonomics (n.d., accessed 20 March 2021).
20.
ArnautovicN.Workers compensation and prescription drugs – 2018 update. Report, National Council on Compensation Insurance, USA, January 2019.
21.
HaightJRSearsJMFulton-KehoeD, et al.
Early high-risk opioid prescribing practices and long-term disability among injured workers in Washington State, 2002 to 2013. J Occup Environ Med2020;
62: 538.
22.
HuntDLArtusoRDKaliaN, et al.
Association of opioid, anti-depressant, and benzodiazepines with workers’ compensation cost a cohort study. J Occup Environ Med2019;
61: e206–e211.
23.
HarnoisGGabrielP, et al. World Health Organization,. Mental health and work: impact, issues and good practices. Report for the World Health Organization. Report no. WHO/MSD/MPS/00.2, 2000. Geneva: WHO.
24.
ChoiB.Opioid use disorder, job strain, and high physical job demands in US workers. Int Arch Occup Environ Health2020;
93: 577–588.
25.
GoplerudEHodgeSBenhamT.A substance use cost calculator for US employers with an emphasis on prescription pain medication misuse. J Occup Environ Med2017;
59: 1063–1071.
CDC Health Alert Network. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic, https://emergency.cdc.gov/han/2020/han00438.asp (2020, accessed 17 December 2020).
DubeyMJGhoshRChatterjeeS, et al.
COVID-19 and addiction. Diabetes Metab Syndr2020;
14: 817–823.
32.
HulseyJMellisAKellyB.COVID-19 pandemic impact on patients, families and individuals in recovery from substance use disorders. Report, Addiction Policy Forum, USA, June 2020.
33.
NagelhoutGEHummelKDe GoeijMCM, et al.
How economic recessions and unemployment affect illegal drug use: a systematic realist literature review. Int J Drug Policy2017;
44: 69–83.
34.
CzeislerMÉLaneRIPetroskyE, et al.
Mental health, substance use, and suicidal ideation during the COVID-19 pandemic – United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep2020;
69: 1049–1057.
35.
GagnonLThompsonMMcHughC, et al. Mental health index: U.S. worker edition. Powerpoint presented at National Alliance of Healthcare Purchaser Coalitions, 2020.
36.
AdamsTReinertMFritzeD, et al. Mind the workplace. Report, Mental Health America, USA, February 2021.
37.
NIDA. Part 1: the connection between substance use disorders and mental illness. Report, National Institute on Drug Abuse, USA, April 2021.
38.
CDC COVID-19 Response Team.
Characteristics of health care personnel with COVID-19 – United States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep2020;
69: 477–481.
39.
ChenYHGlymourMRileyA, et al.
Excess mortality associated with the COVID-19 pandemic among Californians 18-65 years of age, by occupational sector and occupation: March through November 2020. PloS One2021;
16: e0252454.
NetherlandJHansenHB.The war on drugs that wasn’t: wasted whiteness, “dirty doctors,” and race in media coverage of prescription opioid misuse. Cult Med Psychiatry2016;
40: 664–686.
42.
RosinoMLHugheyMW.The war on drugs, racial meanings, and structural racism: a holistic and reproductive approach. Am J Econ Sociol2018;
77: 849–892.
43.
VolkowNDJonesEBEinsteinEB, et al.
Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry2019;
76: 208–216.
KurbinCESquiresGStewartE.Neighborhoods, race, and recidivism: the community reoffending nexus and its implications for African Americans. Sage Race Relat Abstr2007;
32: 7–37.
46.
BoserupBMcKenneyMElkbuliA.Disproportionate impact of COVID-19 pandemic on racial and ethnic minorities. Am Surg2020;
86: 1615–1622.
47.
RosenJHarnettP. Confronting two crises: the COVID-19 pandemic, the opioid epidemic, and the industrial hygienist. New Solut. Epub ahead of print 7 July 2021. DOI: 10.1177/10482911211029580.
YancyCW.COVID-19 and African Americans. JAMA2020;
323: 1891–1892.
50.
ShannonCARospendaKMRichmanJA, et al.
Race, racial discrimination, and the risk of work-related illness, injury or assault: findings from a national study. J Occup Environ Med2009;
51: 441–448.
FinleyEPGarciaARosenK, et al.
Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res2017;
17: 240.
55.
RhodesEWilsonMRobinsonA, et al.
The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Services Res2019;
19: 784.
56.
BonarEECoughlinLRocheJS, et al.
Prescription opioid misuse among adolescents and emerging adults in the United States: a scoping review. Prev Med2020;
132: 105972.
57.
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS report: age of substance use initiation among treatment admissions ages 18 to 30. Report, Rockville, MD, USA, July 2014.
58.
SchepisTSHakesJK.Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically. Subst Abus2017;
38: 407–413.
59.
AttridgeMCahillTGranberrySW, et al.
The national behavioral consortium industry profile of external EAP vendors. J Workplace Behav Health2013;
28: 251–324.
60.
KellyJFBergmanBHoeppnerBB, et al.
Prevalence and pathways of recovery from drug and alcohol problems in the United States population: implications for practice, research, and policy. Drug Alcohol Depend2017;
181: 162–169.
DeRigneLStoddard-DarePQuinnL.Workers without paid sick leave less likely to take time off for illness or injury compared to those with paid sick leave. Health Aff (Millwood)2016;
35: 520–527.
63.
AsfawAPana-CryanRRosaR.Paid sick leave and nonfatal occupational injuries. Am J Public Health2012;
102: e59–e64.
64.
HawkinsDZhJ.Decline in the rate of occupational injuries and illnesses following the implementation of a paid sick leave law in Connecticut. Am J Ind Med2019;
62: 859–873.
LaMontagneADMartinAPageKM, et al.
Workplace mental health: developing an integrated intervention approach. BMC Psychiatry2014;
14: 131.
68.
DobsonKSSzetoAKnaakS.The working mind: a meta-analysis of a workplace mental health and stigma reduction program. Can J Psychiatry2019;
64: 39S–47S.
69.
HoutmanIJettinghoffK, et al. TNO Work & Employment. Raising awareness of stress at work in developing countries. Report, World Health Organization, Switzerland, 2007.
70.
OrnekOKEsinMN.Effects of a work-related stress model based mental health promotion program on job stress, stress reactions and coping profiles of women workers: a control groups study. BMC Public Health2020;
20: 1–4.
71.
HuangSLLiRHHuangFY, et al.
The potential for mindfulness-based intervention in workplace mental health promotion: results of a randomized controlled trial. PLoS One2015;
10: e0138089.
